Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 3/20 | 0.36 |
| ▸ | PER2 | O15055 | 2/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12228958 | 0.88 | PIK3CD (0.59) | PIK3CDKDM4ENAAAPER2CRY2 | |
| SCHEMBL21649532 | 0.86 | PIK3CD (0.53) | PIK3CDKDM4ENAAAPER2CRY2 | |
| SCHEMBL340254 | 0.83 | PIK3CD (0.40) | PIK3CDKDM4ENAAAPER2CRY2 | |
| SCHEMBL15097937 | 0.82 | KDM4E (0.45) | PIK3CDKDM4ENAAAPER2CRY2 | |
| SCHEMBL29817711 | 0.81 | AR (0.42) | PIK3CDKDM4ENAAAPER2CRY2 | |
| SCHEMBL19767304 | 0.80 | KDM4E (0.44) | PIK3CDKDM4ENAAAPER2CRY2 | |
| SCHEMBL261199 | 0.77 | — | — | |
| SCHEMBL4935524 | 0.75 | KDM4E (0.40) | PIK3CDKDM4ENAAANQO2 | |
| SCHEMBL13086572 | 0.75 | PIK3CD (0.40) | PIK3CDKDM4ENAAACNR1CNR2 | |
| SCHEMBL8593693 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-10947237-B2 | Antimicrobial compounds and methods of making and using the same | BioVersys AG (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20180065966-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | MELINTA THERAPEUTICS, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065966-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | MELINTA THERAPEUTICS, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| US-4462865-A | Delignification of lignocellulosic materials with 2-imidazolidinones and 2-oxazolidinones | THE DOW CHEMICAL COMPANY (US) | 1984-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | PTK2B, PRKACA, DSTYK | PIK3CD 728/4885KDM4E 1640/4885NAAA 3514/4885 |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | PIK3CD 2331/4885KDM4E 1441/4885NAAA 2768/4885 |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | PIK3CD 1778/4885KDM4E 2769/4885NAAA 1823/4885 |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | PIK3CD 1785/4885KDM4E 3317/4885NAAA 962/4885 |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | ABL1, ERBB2, TYRO3 | PIK3CD 353/4885KDM4E 1254/4885NAAA 4713/4885 |
| US-20180065966-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | LPO, MPO, CAT | PIK3CD 3383/4885KDM4E 4341/4885NAAA 305/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | PIK3CD 2847/4885KDM4E 3641/4885NAAA 624/4885 |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ABL1, ERBB2, TYRO3 | PIK3CD 353/4885KDM4E 1254/4885NAAA 4713/4885 |
| US-10947237-B2 | Antimicrobial compounds and methods of making and using the same | LPO, MPO, CAT | PIK3CD 3383/4885KDM4E 4341/4885NAAA 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.